Odile Maarek

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.

Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.

Journal: Haematologica

Published: August 02, 2025

Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients.

Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients.

Journal: British journal of haematology

Published: December 18, 2021

Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.

Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.

Journal: Journal of cellular and molecular medicine

Published: July 05, 2021

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.

Journal: Leukemia

Published: November 19, 2019

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Journal: British journal of haematology

Published: March 06, 2018

Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.

Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.

Journal: European journal of haematology

Published: April 29, 2015

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 07, 2013

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.

Journal: British journal of haematology

Published: January 10, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026